Great Bay Bio Invites You to BIO KOREA 2025: Revolutionizing Drug Discovery with AI-Driven Platforms

▲BIO KOREA 2025

ThisThis meeting is expected to attractParticipation from 800 companies and 21,000 attendees across 25 countries globally,Exhibiting companies will showcase their innovative achievements, and visitors can learn about the development trends in the bioprocessing industry.

Dr. Kai Qi, CCO of Great Bay Bio, will attend this conference with the intelligent drug development ecosystem.Show how GBB utilizes cutting-edge technologies like AI to empower the entire process from early drug discovery to subsequent bioprocess development, completing the journey from target/antibody drug discovery to early CMC work within 8 months. Particularly in the high-yield stable cell line construction phase, it has achieved a revolutionary change of obtaining monoclonal cells within 6 weeks and predicting product quality 4 weeks in advance.

▲6 Weeks for Monoclonal & 4 Weeks for Product Quality Prediction